BACKGROUND: Allogeneic stem cell transplantation is associated with a powerful 'graft-versus-leukemia' effect that is generally considered to result from an alloreactive T-cell immune response. However, disease remission can also be observed after syngeneic transplantation and we investigated whether a T-cell immune response to cancer-testis antigens can be detected in patients in the post-transplant period. DESIGN AND METHODS: The T-cell immune response against cancer-testis antigens was studied in a cohort of 41 patients who underwent allogeneic stem cell transplantation for the management of acute myeloid leukemia or multiple myeloma. The cytokine secretion assay was combined with magnetic selection to allow detection of an interferon-gamma-secreting T-cell response to a panel of cancer-testis antigen peptides. RESULTS: A cancer-testis antigen-specific CD8(+) T-cell immune response was observed in the peripheral blood of five patients with an average magnitude of 0.045% of the CD8(+) T-cell repertoire. Four of these patients had undergone reduced intensity conditioning transplantation with alemtuzumab for the treatment of acute myeloid leukemia and three remain in long-term remission. T-cell immunity was focused against peptides derived from MAGE proteins and was markedly increased within the bone marrow. CONCLUSIONS: Functional cancer-testis antigen-specific CD8(+) T-cell immune responses develop in the early period following reduced intensity allogeneic stem cell transplantation and are preferentially localized to bone marrow. These immune responses are likely to contribute to the cellular basis of the graft-versus-leukemia effect.
BACKGROUND: Allogeneic stem cell transplantation is associated with a powerful 'graft-versus-leukemia' effect that is generally considered to result from an alloreactive T-cell immune response. However, disease remission can also be observed after syngeneic transplantation and we investigated whether a T-cell immune response to cancer-testis antigens can be detected in patients in the post-transplant period. DESIGN AND METHODS: The T-cell immune response against cancer-testis antigens was studied in a cohort of 41 patients who underwent allogeneic stem cell transplantation for the management of acute myeloid leukemia or multiple myeloma. The cytokine secretion assay was combined with magnetic selection to allow detection of an interferon-gamma-secreting T-cell response to a panel of cancer-testis antigen peptides. RESULTS: A cancer-testis antigen-specific CD8(+) T-cell immune response was observed in the peripheral blood of five patients with an average magnitude of 0.045% of the CD8(+) T-cell repertoire. Four of these patients had undergone reduced intensity conditioning transplantation with alemtuzumab for the treatment of acute myeloid leukemia and three remain in long-term remission. T-cell immunity was focused against peptides derived from MAGE proteins and was markedly increased within the bone marrow. CONCLUSIONS: Functional cancer-testis antigen-specific CD8(+) T-cell immune responses develop in the early period following reduced intensity allogeneic stem cell transplantation and are preferentially localized to bone marrow. These immune responses are likely to contribute to the cellular basis of the graft-versus-leukemia effect.
Authors: A A Jungbluth; K J Busam; D Kolb; K Iversen; K Coplan; Y T Chen; G C Spagnoli; L J Old Journal: Int J Cancer Date: 2000-02-15 Impact factor: 7.396
Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon Journal: Science Date: 1991-12-13 Impact factor: 47.728
Authors: M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck Journal: Blood Date: 1990-02-01 Impact factor: 22.113
Authors: C H Weaver; R A Clift; H J Deeg; R Storb; F R Appelbaum; W Bensinger; K Doney; J A Hansen; P O Martin; J Sanders Journal: Bone Marrow Transplant Date: 1994-12 Impact factor: 5.483
Authors: Christophe Lonchay; Pierre van der Bruggen; Thierry Connerotte; Takeshi Hanagiri; Pierre Coulie; Didier Colau; Sophie Lucas; Aline Van Pel; Kris Thielemans; Nicolas van Baren; Thierry Boon Journal: Proc Natl Acad Sci U S A Date: 2004-09-27 Impact factor: 11.205
Authors: Pierre Van Der Bruggen; Yi Zhang; Pascal Chaux; Vincent Stroobant; Christophe Panichelli; Erwin S Schultz; Jacques Chapiro; Benoît J Van Den Eynde; Francis Brasseur; Thierry Boon Journal: Immunol Rev Date: 2002-10 Impact factor: 12.988
Authors: J Joseph Melenhorst; Phillip Scheinberg; Pratip K Chattopadhyay; Emma Gostick; Kristin Ladell; Mario Roederer; Nancy F Hensel; Daniel C Douek; A John Barrett; David A Price Journal: Blood Date: 2008-11-07 Impact factor: 22.113
Authors: Amir A Toor; Kyle K Payne; Harold M Chung; Roy T Sabo; Allison F Hazlett; Maciej Kmieciak; Kimberly Sanford; David C Williams; William B Clark; Catherine H Roberts; John M McCarty; Masoud H Manjili Journal: Br J Haematol Date: 2012-07-23 Impact factor: 6.998
Authors: Francis Mussai; Rachel Wheat; Evgenia Sarrou; Sarah Booth; Victoria Stavrou; Livingstone Fultang; Tracey Perry; Pamela Kearns; Paul Cheng; Karen Keeshan; Charles Craddock; Carmela De Santo Journal: Int J Cancer Date: 2019-01-11 Impact factor: 7.396